Press Room - Sanofi US News
Sep 20, 2024 · Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study. Data presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activity.
ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
Sep 23, 2024 · Sanofi’s tolebrutinib significantly delayed disability progression, by 31%, and increased the rates of disability improvement compared with a placebo in people with nonrelapsing...
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Nov 5, 2024 · Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French...
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
Sep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies,...
Sanofi reports data from multiple sclerosis trials of tolebrutinib
Sep 2, 2024 · Sanofi has announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS).
Press Room - Sanofi US News
Feb 24, 2022 · New preclinical data demonstrated that tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), was the only BTK inhibitor with sufficient central nervous system (CNS) exposure and potency to modulate BTK signaling pathways within the CNS, as compared with evobrutinib ...
ECTRIMS 2023: Tolebrutinib show benefits for up to 3 years
Oct 16, 2023 · Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS),...
Feb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
Tolebrutinib Shows Positive Results in Slowing Disability …
Sep 20, 2024 · In a phase 3 study, tolebrutinib demonstrated a statistically significant delay in time to onset of confirmed disability progression in patients living with non-relapsing secondary progressive multiple sclerosis.
- Some results have been removed